Nicotinic antagonists

MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research

Retrieved on: 
Wednesday, March 3, 2021

MINDCURE recognizes the importance of sustainability, excellence, and reliability regarding the materials it uses in product development and research.

Key Points: 
  • MINDCURE recognizes the importance of sustainability, excellence, and reliability regarding the materials it uses in product development and research.
  • By manufacturing ibogaine, MINDCURE's research team will have access to a predictable and standardized supply of synthetic ibogaine, while ensuring consistent dosing and reliable results.
  • Ibogaine has unique and broad actions in the brain, affecting multiple receptors and neurotransmitter systems.
  • Ibogaine offers incredible therapeutic potential, especially in the context of neuroregeneration," said Dr. Ryan Hartwell, Chief Science Officer, MINDCURE.

Ehave Inc. Reaches Milestone; Ketamine IV Therapy Provider KetaDASH to Launch Beta in Second Quarter 2021

Retrieved on: 
Friday, February 26, 2021

MIAMI, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the Company), a provider of digital therapeutics for the psychedelic and mental health sectors, announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology.

Key Points: 
  • MIAMI, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the Company), a provider of digital therapeutics for the psychedelic and mental health sectors, announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology.
  • KetaDASH is a personalized mental care platform designed to instantly connect patients with highly skilled nurses to provide ketamine therapy at home under expert supervision.
  • Ehave has also secured an umbrella policy to cover liability and malpractice insurance on each home delivery service.
  • The KetaDASH platform allows licensed ketamine clinics and patients who have been prescribed ketamine by a physician to administer the treatment at home intravenously.

$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial

Retrieved on: 
Wednesday, February 10, 2021

Bionomics' lead drug BNC210 has already received Fast Track Designation from the FDA and I am confident of the strong potential of the upcoming Phase 2b PTSD trial to drive value for both patients and shareholders."

Key Points: 
  • Bionomics' lead drug BNC210 has already received Fast Track Designation from the FDA and I am confident of the strong potential of the upcoming Phase 2b PTSD trial to drive value for both patients and shareholders."
  • Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (7) nicotinic acetylcholine receptor.
  • Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).
  • Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

SPRAVATO®▼ (Esketamine Nasal Spray) Authorised in Europe for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder

Retrieved on: 
Monday, February 8, 2021

Many antidepressants are effective in treating depressive symptomatology but do not provide rapid relief for patients and can take weeks to achieve their full effect.

Key Points: 
  • Many antidepressants are effective in treating depressive symptomatology but do not provide rapid relief for patients and can take weeks to achieve their full effect.
  • The fast-acting nature of esketamine nasal spray in these patients may address a key unmet need within this population.
  • Esketamine nasal spray offers adults with MDD who are in need of urgent relief, an effective treatment to reduce their debilitating depressive symptoms.
  • This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding SPRAVATO (esketamine nasal spray).

US General Anesthesia Drugs Market worth $2.4 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 4, 2021

Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.

Key Points: 
  • Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.
  • Similarly, intravenous anesthesia drugs are further categorized into propofol, benzodiazepines, ketamine, methohexital sodium and others intravenous general anesthesia drugs.
  • General intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment.
  • Based on end user, the US general anesthesia drugs market has been segmented into hospitals and ambulatory surgery centers.

US General Anesthesia Drugs Market worth $2.4 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 4, 2021

Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.

Key Points: 
  • Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.
  • Similarly, intravenous anesthesia drugs are further categorized into propofol, benzodiazepines, ketamine, methohexital sodium and others intravenous general anesthesia drugs.
  • General intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment.
  • Based on end user, the US general anesthesia drugs market has been segmented into hospitals and ambulatory surgery centers.

Psychedelic Wellness-Focused Company Delic to Acquire Ketamine Infusion Centers LLC

Retrieved on: 
Thursday, February 4, 2021

VANCOUVER, BC, Feb. 4, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce it has entered into a binding letter agreement (the "Letter Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").

Key Points: 
  • VANCOUVER, BC, Feb. 4, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce it has entered into a binding letter agreement (the "Letter Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").
  • KIC will be Strategically Positioned to Leverage DELIC Platform and Brand: DELICexpectsto drive patients to KIC through its media platform and become a national leader
    Established History of Providing Ketamine Infusion Services.
  • By acquiring KIC, DELIC expands from being a central hub of psychedelic education, media, and information to being able to provide patients with psychedelic therapy.
  • DELIC was the first psychedelic umbrella platform and is currently a trusted source for those interested in psychedelic culture, psychedelic clinics, and more.

Ketamine Taskforce for Access to Safe Care and Insurance Coverage Launches, Offering Hope to Chronic Pain and Mental Health Patients

Retrieved on: 
Monday, February 1, 2021

Today, the national Ketamine Taskforce for Access to Safe Care and Insurance Coverage has been launched.

Key Points: 
  • Today, the national Ketamine Taskforce for Access to Safe Care and Insurance Coverage has been launched.
  • The Taskforce has a mission to ensure access for pain and mental health patients to safe ketamine treatments through insurance coverage of the therapies.
  • This has left the tens of millions of Americans experiencing mental health conditions and pain with huge suffering and lack of access to affordable treatments.
  • In light of this heartbreaking reality, the Ketamine Taskforce was created to increase access to lifesaving ketamine treatments.

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine

Retrieved on: 
Monday, February 1, 2021

PharmaTher will incorporate KETABET, its licensed patented formulation that combines FDA-approved ketamine and betaine, with Professor Donnellys patented hydrogel-forming microneedle (MN) patch technology.

Key Points: 
  • PharmaTher will incorporate KETABET, its licensed patented formulation that combines FDA-approved ketamine and betaine, with Professor Donnellys patented hydrogel-forming microneedle (MN) patch technology.
  • The proposed KETABET MN patch offers a potential game-changing therapeutic solution to treat mental health disorders, neurological and pain disorders.
  • Professor Ryan Donnelly commented: Our recent research with esketamine in our patented microneedle technology shows the potential of an alternative delivery method that can overcome the limitations of current ketamine delivery options without comprising the safety and compliance of patients.
  • He is a leading expert and researcher in the field of transdermal delivery with primary focus on microneedle drug delivery and its applications on improving therapeutic outcomes for patients.

Ketamine Media Launches KetaView Magazine to Further Its Mission to Raise Awareness About Treatment Options

Retrieved on: 
Friday, January 29, 2021

KNOXVILLE, Tenn., Jan. 29, 2021 /PRNewswire/ -- Ketamine Media charts new territory in the field of ketamine treatment with the launch of KetaView Magazine, the industry's first dedicated publication.

Key Points: 
  • KNOXVILLE, Tenn., Jan. 29, 2021 /PRNewswire/ -- Ketamine Media charts new territory in the field of ketamine treatment with the launch of KetaView Magazine, the industry's first dedicated publication.
  • The first issue of KetaView is currently available to read in digital format across Ketamine Media's network of websites.
  • About Ketamine Media -In early 2016, Ketamine Media's parent company 360 Media worked with one of the nation's leading providers of ketamine infusion therapy across 8 states.
  • Since then, the team at Ketamine Media has worked tirelessly to design effective outreach tools and processes to help providers raise awareness about the clinical use of ketamine.